Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|18|19|2713-2719

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.18, Iss.19, 2012-06, pp. : 2713-2719

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer

By Troiani Teresa   Martinelli Erika   Orditura Michele   De Vita Ferdinando   Ciardiello Fortunato   Morgillo Floriana  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 949-959

Informa Healthcare

Access to resources Recommend Favorite

VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?

By  

Current Pharmaceutical Design, Vol. 20, Iss. 7, 2014-02 ,pp. : 1041-1044

Bentham Science Publishers

Access to resources Recommend Favorite

New Pharmaceutical Treatment of Gastric MALT Lymphoma: Anti-angiogenesis Treatment using VEGF Receptor Antibodies and Celecoxib

By  

Current Pharmaceutical Design, Vol. 20, Iss. 7, 2014-02 ,pp. : 1097-1103

Bentham Science Publishers

Access to resources Recommend Favorite

Novel targets in esophageal and gastric cancer: beyond antiangiogenesis

By Lee Wooin   Patel Jignesh H   Lockhart A Craig  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 9, 2009-09 ,pp. : 1351-1364

Informa Healthcare

Access to resources Recommend Favorite

Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies

By  

Current Pharmaceutical Design, Vol. 13, Iss. 20, 2007-07 ,pp. : 2025-2044

Bentham Science Publishers

Access to resources Recommend Favorite